tralokinumab (Adtralza)

following a full submission:

tralokinumab (Adtralza®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

SMC restriction: patients who have had an inadequate response to an existing systemic immunosuppressant such as ciclosporin, or in whom such treatment is considered unsuitable.

Four phase III studies demonstrated superiority of tralokinumab in improving signs and symptoms of atopic dermatitis when compared with placebo, as monotherapy or in combination with topical corticosteroids in patients with moderate to severe atopic dermatitis.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.